T he adoption of dual antiplatelet therapy with aspirin and thienopyridines has led to a substantial reduction in the risk of adverse cardiovascular events after percutaneous coronary intervention (PCI). 1, 2 Current clinical practice guidelines strongly endorse the use of dual antiplatelet therapy for at least 12 months after implantation of drugeluting stents, and ideally for 12 months after implantation of bare-metal stents for patients not at risk of bleeding. 3, 4 Although several studies have evaluated factors associated with in-hospital or short-term bleeding after PCI, [5] [6] [7] [8] predictors of late bleeding after PCI have not been adequately studied. Indeed, determinants of late bleeding may differ substantially from early bleeding because many predictors of early bleeding are related to the PCI procedure itself. [5] [6] [7] [8] Important factors such as access site, sheath size, and dosing of antithrombotic agents are unlikely to influence the likelihood of bleeding beyond a few days after the procedure. Furthermore, the majority of studies evaluating bleeding episodes have used data from randomized trials 6 -9 and, therefore, may not have included the broader population of patients at high risk of bleeding commonly encountered in clinical practice.
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Accordingly, the incidence of late bleeding after PCI, its independent predictors, and whether it occurs after PCI is associated with adverse outcomes at the population level are not known. Addressing this gap in knowledge may have important implications for developing strategies to reduce overall risk of bleeding after PCI. Since 2003, all patients aged Ն65 years who received either a drug-eluting stent or a bare-metal stent in Ontario, Canada, were eligible to receive 12 months of thienopyridine under the Ontario Drug Benefit Program at minimal cost. 10 This policy afforded a unique opportunity to achieve our study objectives through a contemporary population-based cohort of patients undergoing PCI.
Methods

Study Sample
We included patients aged Ն65 years who were treated with PCI from December 1, 2003 , to March 31, 2007 . Patients who died during hospitalization were excluded because of the inability to examine late bleeding. Patients who did not receive an intracoronary stent also were excluded because they may not have had an indication to receive thienopyridine therapy. For patients who had multiple PCI procedures during the study period, the first PCI was considered the index procedure.
Data Sources
Data from the Cardiac Care Network of Ontario, a prospective clinical cardiac invasive procedure registry, were used to capture demographic, clinical, and procedural characteristics of patients who underwent PCI. 11, 12 The Ontario Drug Benefit Program prescription claims database, which provides information on prescription drugs dispensed to Ontario residents aged Ն65 years, was used to determine medication use before and after PCI. The agreement rate of the Ontario Drug Benefit prescription claims record and dispensed records from the pharmacy is Ͼ99%. 13 The Canadian Institute for Health Information discharge abstract database, which contains a detailed record of all hospital admissions, was used to capture hospitalizations after the index PCI procedure. It has been previously validated, with agreement rates of 87% for the most responsible diagnosis and 83% for comorbid conditions. 14 The Ontario Registered Persons Database, which contains vital statistics for each Ontario resident, was used to ascertain mortality outcomes. Linkages of these databases were performed using unique encrypted patient identifiers to protect patient confidentiality. 11, 12 This study was approved by the research ethics board at the Sunnybrook Health Sciences Centre (Toronto, Ont, Can).
System Context
The Ontario Ministry of Health and Long-Term Care reimburses all fees relating to cardiac invasive procedures and hospitalizations without patient user fees. 10 In the Ontario Drug Benefit Program, patients are not subject to medication fees but are required to pay a dispensing fee of $6.11 for each medication filled. This dispensing fee is reduced to $2 for patients with low-income status as determined by an annual income of less than $16 018 (US $1ϭCan $1.08 on November 1, 2009).
Outcomes
Our primary outcome was hospitalization for bleeding within 1 year after discharge from the index PCI. Because patients were only eligible to receive 12 months of thienopyridine therapy in Ontario except for rare exceptions, a 1-year period was chosen as our time frame of interest. 10 Bleeding episodes leading to hospitalizations were identified using the International Classification of Diseases, 10th revision (ICD-10) diagnosis codes (online-only Data Supplement Appendix). Bleeding episodes that occurred during the index PCI hospitalization or as an in-hospital complication were excluded. Hospitalization for myocardial infarction (MI) was assessed using ICD-10 codes I21 and I22. Mortality was determined from the Ontario Registered Persons Database. These outcomes were assessed through March 31, 2009, with complete 1-year follow-up data for each outcome.
Statistical Analysis
We first assessed the incidence of hospitalization for bleeding episodes using Kaplan-Meier methods. We categorized bleeding hospitalizations into gastrointestinal, urologic, neurological, pulmonary-related, and other unclassified causes (supplemental Appendix). Demographics, clinical characteristics, and medication use of patients who experienced late bleeding were compared with those who did not, using 2 tests for categorical variables and t tests for continuous variables. Second, we identified independent predictors of late bleeding after PCI using Cox proportional hazard models. Candidate variables of interest included demographics (age, sex, low income), cardiac risk factors, medical comorbidities, procedural characteristics (baremetal stents, drug-eluting stents), and medication use. The prescription claims database includes prescription date and duration for each medication, which allowed us to estimate current medication use continuously after the index PCI. Each medication was modeled as a time-varying exposure to assess the relationship of current medica- tion use and bleeding. This analytic method allowed patients to start and stop each medication without the need of classifying medication use based on a fixed period of time. This method was necessary because significant medication changes for bleeding may occur after hospitalization, and we would have misclassified medication use if it was categorized according to a fixed time period. In essence, we estimated the effect of current medication exposure on the instantaneous hazard of bleeding. Third, the association of hospitalization for bleeding on subsequent death or MI (as a composite outcome) was examined using a Cox proportional hazards regression model. Hospitalization for bleeding was treated as a time-varying covariate. The regression model was adjusted for the effect of potential confounders as described earlier. We also examined the association of hospitalization for bleeding on death and MI separately. Time to 1-month events and time to 1-year events were calculated to evaluate the relationship of bleeding with short-and long-term adverse outcomes.
All analyses were performed using SAS software version 9.1. Statistical significance was defined as a 2-tailed PϽ0.05.
Results
Characteristics of Patients With and Without Hospitalization for Bleeding
After applying the inclusion and exclusion criteria, our cohort included 22 798 patients aged Ն65 years who underwent PCI. The mean age of our cohort was 73.6 years, 62.2% were men, and 38% had an acute MI in the past year (Table 1) . Before PCI, 7.5% of the overall cohort was prescribed oral anticoagulation with warfarin, 12.9% nonsteroidal antiinflammatory drugs (NSAIDs), and 25.2% proton-pump inhibitors (PPIs) ( Table 1 ). In the year after PCI, 93.5% of patients in our cohort were prescribed thienopyridine, 12.8% oral anticoagulants, 16.1% NSAIDs, and 40.2% PPIs.
Patients hospitalized for bleeding were older and more likely to have hypertension, a history of stroke or transient ischemic attack, chronic obstructive pulmonary disease, heart failure, peripheral vascular disease, cancer, chronic kidney disease, and a hospitalization for bleeding in the past year (Table 1) . Patients who had bleeding episodes also were more likely to be prescribed oral anticoagulants before PCI (Table 1) .
Hospitalization for Bleeding After Discharge From Index PCI
The 1-year rate of hospitalization for bleeding after discharge from PCI was 2.5% ( Table 2 ). Incidence of hospitalizations for bleeding was 4.3% in patients who were aged Ͼ85 years, 5.0% in those with a history of cancer, 3.8% in those with a prior stroke or transient ischemic attack, 6.1% in those with chronic kidney disease, and 7.6% in those who had a hospitalization for bleeding in the previous year. The incidence of bleeding among patients prescribed oral anticoagulation with warfarin within 90 days of the bleeding episodes was 6.4%.
Gastrointestinal bleeding accounted for the majority (55.8%) of episodes of late bleeding in the year after PCI ( Table 2 ). The incidence of bleeding at 1 year was 1.4% for gastrointestinal bleeding, 0.42% for other unclassified bleeding, 0.32% for urologic bleeding, 0.18% for neurological bleeding, and 0.18% for pulmonary-related bleeding. Figure 1 illustrates the Kaplan-Meier curve of bleeding episodes requiring hospitalization after discharge from PCI. The incidence was highest at 0.68% in the first month after PCI (95% CI, 0.57% to 0.79%) and at 0.17% per month (95% CI, 0.15% to 0.18%) between 1 month and 1 year. The increased incidence of early bleeding was related in part to a greater incidence of gastrointestinal bleeding in the first month after PCI.
Independent Predictors Associated With Late Bleeding After PCI
Independent factors associated with increased hazards of late bleeding are shown in Figure 2 and Table 3 . These factors included age, male sex, cancer, prior bleeding, chronic kidney disease, oral anticoagulant use with warfarin, and NSAID use. Among these factors, oral anticoagulant use was associated with the greatest hazard of bleeding, a 3.2-fold increased risk. For each 10-year increase in age, there was a 1.5-fold increased risk in late bleeding. PPIs, other gastroprotective agents, or thienopyridine therapy were not significantly associated with bleeding.
Independent factors associated with increased hazards of late gastrointestinal bleeding were similar to the overall bleeding model that included age, prior hospitalization for bleeding, chronic kidney disease, oral anticoagulant use, and NSAID use ( Figure 3 and Table 4 ). Again, oral anticoagulation with warfarin was associated with the greatest hazard of 
Association of Late Bleeding With Adverse Outcomes
Of the 573 patients who had bleeding after PCI, the composite rate of death or MI was 6.1% at 30 days and 20.4% at 1 year after hospitalization for bleeding. The majority of events were deaths. Death rates were 4.4% at 30 days and 14.1% at 1 year, and MI rates were 1.7% at 30 days and 7.9% at 1 year (Table 5 ). Even after adjusting for important demographics and potential confounding factors, bleeding was associated with a significantly increased hazard of death or MI at 1 year (HR, 2.39; 95% CI, 1.93 to 2.97) ( Table 5 ). Hospitalization for bleeding also was associated with a substantially increased adjusted hazard of death (HR, 3.38; 95% CI, 2.60 to 4.40) at 1 year (Table 5 ).
Discussion
In this contemporary population-based study where almost all patients were prescribed thienopyridine after PCI, we found that 2.5% of older patients were hospitalized for bleeding in the year after their PCI procedure. More than half (56%) of these hospitalizations for bleeding were due to gastrointestinal bleeding. Importantly, bleeding was associated with a 2-fold increased hazard of death or MI and a 3-fold increased hazard of death within 1 year, even after adjustment for important demographics and clinical characteristics. Several independent predictors of late bleeding were identified that may allow physicians to identify patients at high risk for late bleeding. Most noticeably, clinicians should be aware that the use of triple therapy (ie, aspirin, thienopyridine, and warfarin) was the strongest predictor of late bleeding, which was associated with a Ͼ3-fold increased hazard of late bleeding after PCI.
Our study extends previous findings on the incidence of late bleeding that have been primarily drawn from randomized trials. In the Clopidogrel for Reduction of Events During Observation trial that randomized patients after PCI on aspirin to 1 month versus 1 year of clopidogrel, the incidence of nonprocedural major bleeding in the prolonged clopidogrel group was 1.2%. 15 In the PCI subgroup of the Clopidogrel in Unstable angina to prevent Recurrent Events study, the incidence of major bleeding was 1.1% from 30 days to a mean duration of 9 months for patients who were randomized to aspirin and clopidogrel. 16 Our higher bleeding rate of 2.5% is likely a reflection of our real-world PCI cohort, which is older and has more medical comorbidities than patients typically enrolled in trials. To put these rates of bleeding in perspective, the annual bleeding rates in atrial fibrillation trials were 1.3% per year on warfarin and 2.2% per year on aspirin and warfarin. 17 Our study is among the first to demonstrate the strong prognostic importance of late bleeding after PCI for death and MI in routine clinical practice. We also found very poor patient outcomes after hospitalization for bleeding. Specifically, 6% of older patients suffered death or MI at 1 month, and 1 in 5 patients suffered death or MI at 1 year after hospitalization for bleeding. We lacked data elements to categorize causes of death and were unable to identify mechanisms underlying these adverse events. Although greater burden of comorbidities among patients who had bleeding may play a role, the association of late bleeding with MI and death remained significant after adjustment. Previous studies suggested that the cause of adverse outcomes after bleeding episodes is multifactorial. 18 First, the bleeding episode itself is associated with morbidity and mortality, even among patients without a prior cardiac history or cardiac procedure, by means of its location (eg, intracranial bleed) and the extent of blood loss. 18 Bleeding also may lead to a hypercoagulable state, posing a risk to patients who had recently undergone PCI and received intracoronary stents. 18 Second, studies have shown the potential adverse impact of blood transfusion due to impairment of oxygen delivery and its prothrombotic effect. 19 Third, bleeding may lead to withdrawal of warfarin therapy, which has been shown to be associated with substantially high mortality rates in subgroups of patients with atrial fibrillation and PCI. 20 Finally, bleeding may lead to premature discontinuation of antiplatelet therapy, which has been consistently shown to be associated with substantially higher risk of stent thrombosis, MI, and death after PCI. 10, 21, 22 Given the strong association of late bleeding with adverse outcomes, an improved understanding of the determinants of late bleeding may promote strategies to reduce bleeding and may lead to improved outcomes. We found oral anticoagulation use with warfarin to be associated with the highest adjusted hazard for late bleeding after PCI. In addition, we found that NSAID use was associated with a doubling of the hazard of late bleeding. These medications were commonly prescribed, as 1 of 6 patients received oral anticoagulants or NSAIDs in the year after PCI. Actionable strategies to potentially reduce the risk of late bleeding in these patients may include prescribing low-dose aspirin beyond 30 days after stent implantation and carefully assessing the need for long-term oral anticoagulants and NSAIDs. 23, 24 In patients who truly require triple therapy of aspirin, thienopyridine, and warfarin, strategies may include a greater use of baremetal stents and shorter duration or dual antiplatelet therapy and ensuring an appropriate international normalized ratio while on oral anticoagulants because many patients in clinical practice have international normalized ratios beyond the therapeutic window. 25 Several working groups recently have provided expert consensus to assist the management of patients with atrial fibrillation with acute coronary syndrome and undergoing PCI. 26, 27 Similar to previous studies evaluating risk factors for in-hospital bleeding, [5] [6] [7] [8] we also found that older patients and those with chronic kidney disease, a history of stroke or transient ischemic attack, or a history of bleeding were much more likely to have bleeding episodes leading to hospitalization. In contrast, although several studies have consistently demonstrated that female patients are at higher risk for in-hospital bleeding, we found that male patients were actually slightly more likely to bleed at long term. We do not know the reasons for these divergent findings, but similar observations have been made in other studies of late bleeding. 28, 29 Although a recent consensus statement suggests that patients at higher risk for gastrointestinal bleeding on dual antiplatelet therapy should receive prophylaxis with PPIs, 30 we did not detect a significant reduction in the hazard of late gastrointestinal bleeding associated with PPIs or other gastroprotective agents. The lack of protective association may be explained by incomplete adjustment for potential confounders of gastrointestinal bleeding, such as alcohol use, history of peptic ulcer disease, or dyspeptic symptoms. Recent observational studies suggested a potential adverse interaction between clopidogrel and PPIs 31, 32 ; however, conflicting evidence is emerging from a randomized trial showing potential gastrointestinal benefits of this combination. 33 Future studies are needed to explore the net risk or benefit associated with routine prophylaxis with PPIs during dual antiplatelet therapy.
In our study, we did not find a significantly increased hazard of bleeding associated with thienopyridine therapy in contrast to other studies consistently demonstrating a strong association between bleeding and dual antiplatelet therapy. 23, 28, 34 This finding might be explained by the fact that the vast majority of patients who underwent PCI in our cohort were already receiving dual antiplatelet therapy and that we had limited ability to detect the association between thienopyridine therapy and bleeding. One also would hypothesize that the use of drug-eluting stents is associated with increased bleeding because of a greater Model adjusted for age, sex, low income, comorbid conditions, medication use, type of stent implantation as shown in Table 1 . Only significant factors are shown.
*Anticoagulants and NSAIDs modeled as time-varying exposure and estimated the effect of current exposure on the instantaneous hazard of bleeding. need for prolonged dual antiplatelet therapy. The lack of association between bleeding and type of stent implantation in our study is likely explained by the fact that prolonged thienopyridine therapy also was prescribed to the majority of patients with bare-metal stents in Ontario. 10 Several limitations of our study merit discussion. First, we assessed hospitalization for bleeding as our main outcome and were unable to assess major or minor bleeding, as commonly reported by randomized trials, due to a lack of necessary laboratory data elements. However, it has been demonstrated that bleeding episodes identified with clinical criteria may be even more prognostically important than those identified by laboratory criteria. 35 Second, our study was limited to an older cohort (aged Ͼ65 years) because we did not have information on medication use for younger patients. However, older patients represent a vulnerable group with high baseline cardiovascular risk and a greater propensity for bleeding. 34, 36, 37 Third, we did not have utilization rates or prescribed dosages of aspirin because the majority of patients in Ontario purchase aspirin over the counter rather than by prescription claims. Finally, although we found a strong association of late bleeding and adverse outcomes, our study cannot definitively prove a causal relationship given the complex interplay among comorbidities, late bleeding, and adverse outcomes.
In conclusion, in this population-based cohort of older patients who underwent PCI, hospitalization for late bleeding after PCI is associated with a substantially increased risk of death and MI in both the short and the long term. Clinicians should identify patients at risk for late bleeding after PCI and implement strategies to reduce overall risk of bleeding, thereby improving patient outcomes.
CLINICAL PERSPECTIVE
Previous data on bleeding after percutaneous coronary intervention (PCI) have been obtained primarily from randomized trials that focused on in-hospital bleeding. The incidence of late bleeding after PCI, its independent predictors, and its prognostic importance in clinical practice have not been fully addressed. In this population-based study, we evaluated 22 798 patients aged Ͼ65 years who underwent PCI from December 1, 2003 , to March 31, 2007 , in Ontario, Canada. Late bleeding was defined as hospitalization for bleeding after discharge from the index PCI. We found that 2.5% of patients were hospitalized for bleeding in the year after PCI, with 56% of bleeding episodes due to gastrointestinal bleed. Warfarin use after PCI was associated with the greatest hazard (hazard ratio, 3.12) for late bleeding. Even after adjusting for baseline covariates, hospitalization for a bleeding episode was associated with a significant 2-fold increased hazard (hazard ratio, 2.39; 95% CI, 1.93 to 2.97) in 1-year death or myocardial infarction and 3-fold increased hazard (hazard ratio, 3.38; 95% CI, 2.60 to 4.40) in death. Our findings demonstrate that late bleeding after PCI is associated with substantially increased risk of death and myocardial infarction. The use of triple therapy (ie, aspirin, thienopyridine, and warfarin) is associated with the highest risk of late bleeding in clinical practice.
